Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Momenta Pharmaceuticals (MNTA) PT Raised to $15 at Stifel Following Positive M281 MAD Data, EYLEA Biosimilar Unveiling
January 5, 2018 12:40 PM ESTStifel analyst Alex Schwartz raised his price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $15.00 (from $12.00) while maintaining a Hold rating after the company announced positive topline data from the Phase 1 trial with M281.
Schwartz commented, "The anti-FcRn antibody demonstrated a favorable safety profile... More
Mylan (MYL) PT Raised to $44 at BofA/Merrill Lynch Following Generic Estrace Cream Approval
January 4, 2018 8:08 AM ESTBofA/Merrill Lynch raised its price target on Mylan (NASDAQ: MYL) to $44.00 (from $41.00) while maintaining a Neutral rating following the recent approval of generic Estrace Cream, Allergans womens health brand with $375m net sales. MYL recently launched (12/29) g-Estrace followed by an authorized... More
